These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 9014441)

  • 21. Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease.
    Limousin P; Krack P; Pollak P; Benazzouz A; Ardouin C; Hoffmann D; Benabid AL
    N Engl J Med; 1998 Oct; 339(16):1105-11. PubMed ID: 9770557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Depressive symptoms and motor condition in Parkinson's disease patients].
    Stella F; Bucken-Gobbi LT; Gobbi S; Sant'Ana-Simões C
    Rev Neurol; 2007 Nov 16-30; 45(10):594-8. PubMed ID: 18008264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
    Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
    Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Computational analysis of open loop handwriting movements in Parkinson's disease: a rapid method to detect dopamimetic effects.
    Eichhorn TE; Gasser T; Mai N; Marquardt C; Arnold G; Schwarz J; Oertel WH
    Mov Disord; 1996 May; 11(3):289-97. PubMed ID: 8723147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
    Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
    Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Problems of long-term levodopa therapy in Parkinson's disease].
    Nakamura Y
    Nihon Rinsho; 1997 Jan; 55(1):65-71. PubMed ID: 9014425
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioids and motor complications in Parkinson's disease.
    Samadi P; Bédard PJ; Rouillard C
    Trends Pharmacol Sci; 2006 Oct; 27(10):512-7. PubMed ID: 16908075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tremor in Parkinson's disease: 24-hr monitoring with calibrated accelerometry.
    Thielgen T; Foerster F; Fuchs G; Hornig A; Fahrenberg J
    Electromyogr Clin Neurophysiol; 2004; 44(3):137-46. PubMed ID: 15125053
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Abnormal head nociceptive withdrawal reaction to facial nociceptive stimuli in Parkinson's disease.
    Perrotta A; Serrao M; Bartolo M; Valletta L; Locuratolo N; Pujia F; Fattapposta F; Bramanti P; Amabile GA; Pierelli F; Parisi L
    Clin Neurophysiol; 2005 Sep; 116(9):2091-8. PubMed ID: 16029959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease.
    Cools R
    Neurosci Biobehav Rev; 2006; 30(1):1-23. PubMed ID: 15935475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of deep brain stimulation and medication on bradykinesia and muscle activation in Parkinson's disease.
    Vaillancourt DE; Prodoehl J; Verhagen Metman L; Bakay RA; Corcos DM
    Brain; 2004 Mar; 127(Pt 3):491-504. PubMed ID: 14662520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rating scale and functional prognosis of Parkinson's disease].
    Nakano I; Fujimoto K
    Nihon Rinsho; 2000 Oct; 58(10):2132-8. PubMed ID: 11068460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of the motor complications of Parkinson's disease on the quality of life.
    Chapuis S; Ouchchane L; Metz O; Gerbaud L; Durif F
    Mov Disord; 2005 Feb; 20(2):224-30. PubMed ID: 15384126
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease].
    Eichhorn TE; Schrag A; Trenkwalder C; Selzer R; Kohnen R; Oertel WH; Poewe W
    Nervenarzt; 1995 Dec; 66(12):933-41. PubMed ID: 8584079
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypokinesia in Parkinson's disease: influence of age, disease severity, and disease duration.
    van Hilten JJ; Braat EA; van der Velde EA; Middelkoop HA; van Dijk JG; Lighart GJ; Roos RA
    Mov Disord; 1995 Jul; 10(4):424-32. PubMed ID: 7565821
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease.
    Mochio S; Sengoku R; Kono Y; Morita M; Mitsumura H; Takagi S; Kamiyama T; Oka H
    Parkinsonism Relat Disord; 2012 Aug; 18(7):906-8. PubMed ID: 22546334
    [No Abstract]   [Full Text] [Related]  

  • 39. Qualitative Evaluation of the Personal KinetiGraphTM Movement Recording System in a Parkinson's Clinic.
    Santiago A; Langston JW; Gandhy R; Dhall R; Brillman S; Rees L; Barlow C
    J Parkinsons Dis; 2019; 9(1):207-219. PubMed ID: 30412506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A correlation study between blink reflex habituation and clinical state in patients with Parkinson's disease.
    Matsumoto H; Noro H; Kaneshige Y; Chiba S; Miyano N; Motoi Y; Yanada Y
    J Neurol Sci; 1992 Feb; 107(2):155-9. PubMed ID: 1564513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.